Q-omics provides the consensus-scored FAM240C profile across patient tissues and cancer cell-line models. FAM240C expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM240C is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FAM240C RNA expression shows 15,085 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where FAM240C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM240C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM240C survival associations across molecular data types. FAM240C RNA expression shows survival associations in the most cancer types (15), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM240C RNA expression–survival associations across cancer types. High FAM240C expression shows unfavorable associations in KIRC, UVM, CHOL and STAD, but favorable associations in THYM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM240C RNA expression.
This table summarizes FAM240C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM240C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM240C shows lower tumor expression in HNSC, THCA, KICH, KIRC, BLCA and BRCA. The HNSC box plot shows higher FAM240C RNA expression in normal versus tumor tissue (log2 FC = −2.088, t-test p < 0.001).
This table shows molecular features associated with FAM240C in patient tissues and cancer cell lines. In patient samples, FAM240C shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
